These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38373846)

  • 1. Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics.
    Le Tilly O; Gatault P; Semlali S; Sberro-Soussan R; Passot C; Bertrand D; Desvignes C; Caillard S; Paintaud G; Halimi JM; Ternant D
    Br J Clin Pharmacol; 2024 May; 90(5):1312-1321. PubMed ID: 38373846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment.
    Volokhina E; Wijnsma K; van der Molen R; Roeleveld N; van der Velden T; Goertz J; Sweep F; Brüggemann RJ; Wetzels J; van de Kar N; van den Heuvel L
    Clin Pharmacol Ther; 2017 Oct; 102(4):671-678. PubMed ID: 28295239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.
    Gatault P; Brachet G; Ternant D; Degenne D; Récipon G; Barbet C; Gyan E; Gouilleux-Gruart V; Bordes C; Farrell A; Halimi JM; Watier H
    MAbs; 2015; 7(6):1205-11. PubMed ID: 26337866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
    Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
    Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.
    Volokhina EB; van de Kar NC; Bergseth G; van der Velden TJ; Westra D; Wetzels JF; van den Heuvel LP; Mollnes TE
    Clin Immunol; 2015 Oct; 160(2):237-43. PubMed ID: 26111482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study.
    Passot C; Sberro-Soussan R; Bertrand D; Caillard S; Schvartz B; Domenger C; Contin-Bordes C; Paintaud G; Halimi JM; Ternant D; Gatault P
    Br J Clin Pharmacol; 2021 May; 87(5):2236-2246. PubMed ID: 33118186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy.
    Pau Parra A; Ramos N; Perurena-Prieto J; Manrique-Rodríguez S; Climente M; García Quintanilla L; Escolano Á; Miarons M;
    Farm Hosp; 2024; 48(1):16-22. PubMed ID: 37612186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Translated article] Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy.
    Parra AP; Ramos N; Perurena-Prieto J; Manrique-Rodríguez S; Climente M; Quintanilla LG; Escolano Á; Miarons M;
    Farm Hosp; 2024; 48(1):T16-T22. PubMed ID: 38057242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome.
    Ryan M; Donato BMK; Irish W; Gasteyger C; L'Italien G; Laurence J
    Pharmacoeconomics; 2020 Mar; 38(3):307-313. PubMed ID: 31828738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective.
    Ter Avest M; Bouwmeester RN; Duineveld C; Wijnsma KL; Volokhina EB; van den Heuvel LPWJ; Burger DM; Wetzels JFM; van de Kar NCAJ; Ter Heine R;
    Nephrol Dial Transplant; 2023 Feb; 38(2):362-371. PubMed ID: 35238929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient.
    Bouwmeester RN; Ter Avest M; Wijnsma KL; Duineveld C; Ter Heine R; Volokhina EB; Van Den Heuvel LPWJ; Wetzels JFM; van de Kar NCAJ
    Front Immunol; 2020; 11():612706. PubMed ID: 33519821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
    Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
    Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.
    Wijnsma KL; Ter Heine R; Moes DJAR; Langemeijer S; Schols SEM; Volokhina EB; van den Heuvel LP; Wetzels JFM; van de Kar NCAJ; Brüggemann RJ
    Clin Pharmacokinet; 2019 Jul; 58(7):859-874. PubMed ID: 30758736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
    Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
    Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
    Wijnsma KL; Duineveld C; Wetzels JFM; van de Kar NCAJ
    Pediatr Nephrol; 2019 Nov; 34(11):2261-2277. PubMed ID: 30402748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report.
    Alabdulqader M; Alfakeeh K
    BMC Nephrol; 2021 Apr; 22(1):140. PubMed ID: 33879077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
    Fakhouri F; Fila M; Provôt F; Delmas Y; Barbet C; Châtelet V; Rafat C; Cailliez M; Hogan J; Servais A; Karras A; Makdassi R; Louillet F; Coindre JP; Rondeau E; Loirat C; Frémeaux-Bacchi V
    Clin J Am Soc Nephrol; 2017 Jan; 12(1):50-59. PubMed ID: 27799617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.